HIGHLIGHTS
- who: Gian Marco Leone et al. from the Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy have published the paper: Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer, in the Journal: Pharmaceutics 2023, 15, 1252. of /2023/
- what: The studies aimed to uncover both the safety and efficacy of larotrectinib when administered to adults, adolescents, and children with solid tumors harboring NTRK gene fusions. The study showed more benefits in terms of DOR, median OS, and median PFS, which were 35.2, 44.4, and 28.3 months . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.